Podcasts about epithelial

A look at ovarian cancer including ovarian cancer subtypes (Epithelial and its subtypes, Germ Cell, Sex Cord Stromal)  as well as the signs and symptoms of ovarian cancer and ovarian cancer risk factors. We also take a look at how ovarian cancer is staged (FIGO Staging of Ovarian Cancer) and how that affects the prognosis and treatment. PDFs available here: https://rhesusmedicine.com/pages/gynecologyConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 Ovarian Cancer Epidemiology0:36 Ovarian Cancer Risk Factors1:05 Ovarian Cancer Subtypes Intro2:30 Epithelial Ovarian Cancer3:33 Ovarian Cancer Signs and Symptoms4:28 Ovarian Cancer Diagnosis7:04 Ovarian Cancer TreatmentLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/References:BMJ Best Practice (2025) Ovarian cancer: symptoms, diagnosis and treatment. Available at: https://bestpractice.bmj.com/topics/en-gb/260MSD Manuals Professional Edition (2025) Ovarian, Fallopian Tube, and Peritoneal Cancer. Available at: https://www.msdmanuals.com/professional/gynecology-and-obstetrics/gynecologic-tumors/ovarian-fallopian-tube-and-peritoneal-cancerAmerican Cancer Society (2025) Ovarian Cancer Stages. Available at: https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/staging.htmlDisclaimer: Please remember this video and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Guest: Dr. Hans Clevers is a Professor of Molecular Genetics and Distinguished Group Leader at the University of Utrecht. In this episode, he discusses snake gut and lung organoids, transitioning from academia to industry, and the challenges and complexities of creating a cell therapy. (44:26) Featured Products and Resources: Registration and abstracts are open for the ISSCR 2026 annual meeting. Receive an offer to try IntestiCult in your lab. The Stem Cell Science Round Up Computers Made From Human Brain Cells – Researchers have shown that structured neuronal firing sequences appear in spontaneous activity of human and murine brain organoids. (2:37) Organoids Replicate Vascular Pathology – Scientists have developed a blood vessel organoid model from Hutchinson-Gilford progeria syndrome-mutant hESCs. (12:01) Effects of Spaceflight on Stem Cells – Analyses of nine astronauts before, during, and after three short-duration International Space Station missions shows space-associated stem cell hallmarks of aging and resilience. (21:14) The Role of Lysosomes in HSC Aging – Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells. (33:25) Photo Reference: Courtesy of Hans Clevers Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

The episode discusses adnexal masses, specifically epithelial neoplasms. The conversation also highlights the importance of understanding these neoplasms for effective management. (Originally released August 2019) Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: www.facebook.com/creogsovercoffee Website: www.creogsovercoffee.com Patreon: www.patreon.com/creogsovercoffee Visit www.acog.org to learn more about the CREOG National Residency Curriculum coming Fall 2025.

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Faina Nakhlis the upgrade rate to ductal carcinoma in situ or invasive cancer following excision for patients diagnosed with flat epithelial atypia on core biopsy, as reported in the article, "Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).”

Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.​3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.​3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9 Bhattacharyya N, et al. Laryngoscope. 2019;129:1969-1975. van der Veen J, et al. Allergy. 2017;72:282-290. Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133-1141. ©2024 Amgen and AstraZeneca. All rights reserved.US-96000 Last Updated 12/24

In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP. ©2025 Amgen and AstraZeneca. All rights reserved.US-94728 Last Updated 1/25

Certain CD4+ T-cell subtypes play a role in asthma. Characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma. Author Juan C. Celedon, MD, DrPH, University of Pittsburgh, Department of Pediatrics, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content: Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

Epithelium is one of the four basic tissue types (the other three are muscle tissue, nerve tissue, and connective tissue). It is found throughout the body—covering it; lining organs, vessels, and cavities; and forming glands. It absorbs nutrients, transports electrolytes, secretes hormones, and regulates body temperature by producing sweat. We begin with some general principles of how epithelial tissue is organized, and then we describe its various components. After listening to this AudioBrick, you should be able to: List the two types of epithelium (covering/lining and glandular) and describe their functions. Describe the structure and histologic features of epithelial tissue. Explain how covering/lining epithelium is classified. Describe the histologic features of glandular epithelium. Describe the five types of epithelial intercellular junctions. You can also check out the original brick on the Histology of Epithelial Tissue from our Musculoskeletal, Skin, and Connective Tissue collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/

BUFFALO, NY- July 17, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 13, entitled, “Modulating in vitro lung fibroblast activation via senolysis of senescent human alveolar epithelial cells.” Idiopathic pulmonary fibrosis (IPF) is an age-related disease with poor prognosis and limited therapeutic options. Activation of lung fibroblasts and differentiation to myofibroblasts are the principal effectors of disease pathology, but damage and senescence of alveolar epithelial cells, specifically type II (ATII) cells, has recently been identified as a potential trigger event for the progressive disease cycle. Targeting ATII senescence and the senescence-associated secretory phenotype (SASP) is an attractive therapeutic strategy; however, translatable primary human cell models that enable mechanistic studies and drug development are lacking. In this new study, researchers Joseph S. Spina, Tracy L. Carr, Lucy A. Phillips, Heather L. Knight, Nancy E. Crosbie, Sarah M. Lloyd, Manisha A. Jhala, Tony J. Lam, Jozsef Karman, Meghan E. Clements, Tovah A. Day, Justin D. Crane, and William J. Housley from AbbVie Bioresearch Center and Northeastern University describe a novel system of conditioned medium (CM) transfer from bleomycin-induced senescent primary alveolar epithelial cells (AEC) onto normal human lung fibroblasts (NHLF) that demonstrates an enhanced fibrotic transcriptional and secretory phenotype compared to non-senescent AEC CM treatment or direct bleomycin damage of the NHLFs. “In the current study, we confirm the presence of senescent cell populations within the human IPF lung, as well as assess primary cell reagents for sensitivity to senescent cell targeting therapies.” In this system, the bleomycin-treated AECs exhibited classical hallmarks of cellular senescence, including SASP and a gene expression profile that resembles aberrant epithelial cells of the IPF lung. Fibroblast activation by CM transfer was attenuated by pre-treatment of senescent AECs with the senolytic Navitoclax and AD80, but not with the standard of care agent Nintedanib or senomorphic JAK-targeting drugs (e.g., ABT-317, ruxolitinib). This model provided a relevant human system for profiling novel senescence-targeting therapeutics for IPF drug development. “Taken together, the model described herein provides a physiologically relevant, primary human cell system to study the effects of alveolar epithelial cell senescence on lung fibroblasts in the context of chronic fibrotic lung disease.” DOI - https://doi.org/10.18632/aging.205994 Corresponding author - Tovah A. Day - t.day@northeastern.edu Video short - https://www.youtube.com/watch?v=rpmo2PlGDKc Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205994 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of Nantes was reported at the 2024 ASCO Annual Meeting. The researchers noted this surgical de-escalation allows significant reduction of serious post-operative morbidity After the session, Oncology Times correspondent Peter Goodwin learned about more study details from Jean-Marc Classe, MD, PhD, Professor of Surgery in the Department of Surgical Oncology in the Institut de Cancérologie de l'Ouest and Nantes University in Western France.

Dr. Sunad Rangarajan chats with Dr. Corrine Kliment about her article, "Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis." 

I read from epistemic to epithelial.     You've never heard of Griffin and Sabine? https://en.wikipedia.org/wiki/The_Griffin_and_Sabine_Saga     Here are the 2 episodes from "The Allusionist" about epitaphs and engraving. https://www.theallusionist.org/allusionist/epitaph https://www.theallusionist.org/allusionist/precious     The word of the episode is "epistemology". https://en.wikipedia.org/wiki/Epistemology     Theme music from Jonah Kraut https://jonahkraut.bandcamp.com/     Merchandising! https://www.teepublic.com/user/spejampar     "The Dictionary - Letter A" on YouTube   "The Dictionary - Letter B" on YouTube   "The Dictionary - Letter C" on YouTube   "The Dictionary - Letter D" on YouTube   "The Dictionary - Letter E" on YouTube     Featured in a Top 10 Dictionary Podcasts list! https://blog.feedspot.com/dictionary_podcasts/     Backwards Talking on YouTube: https://www.youtube.com/playlist?list=PLmIujMwEDbgZUexyR90jaTEEVmAYcCzuq     https://linktr.ee/spejampar dictionarypod@gmail.com https://www.facebook.com/thedictionarypod/ https://www.threads.net/@dictionarypod https://twitter.com/dictionarypod https://www.instagram.com/dictionarypod/ https://www.patreon.com/spejampar https://www.tiktok.com/@spejampar 917-727-5757

Dr. John Fleetham chats with Dr. Barbro N Melgert and Dr. Chris Carlsten about their articles, "Inhalable Textile Microplastic Fibers Impair Airway Epithelial Differentiation" and "Inhaled Microplastics and Airway Development: Concerning Evidence from Organoids."

Today we discuss the different characteristics of epithelial tissue within biblical anatomy and physiology. We pray that our message encourages you and that you will seek the Bible more fervently, verifying the truth God built into our design. Blessing to each of you.Academy https://community.araratphysiology.com/plans/316165?bundle_token=081501826a1e9918c48eb8c22ea650c5&utm_source=manualSocial Links YouTube (https://www.youtube.com/channel/UCnHjsFTGl9PRWCtO_8BqLgA) Tik Tok (https://www.tiktok.com/@biblicalanatomyacademy) Facebook (https://www.facebook.com/biblicalanatomyacademy) Instagram (https://www.instagram.com/biblicalanatomyacademy/) LinkedIn (https://www.linkedin.com/company/biblicalanatomyacademy/?viewAsMember=true) Rumble (https://rumble.com/user/BiblicalAnatomyAcademy) X (https://twitter.com/BiblicalAnatomy)Contact podcast@DiscipleshipConditioning.com https://sleek.bio/biblicalanatomyacademyDiscipleship Conditioning Podcast Apple Podcasts (https://podcasts.apple.com/us/podcast/discipleship-conditioning/id1674545718) Spotify Podcasts (https://open.spotify.com/show/73WIVyB9V0ptqzxfK2PX1f)Biblical Anatomy Podcast

BUFFALO, NY- October 2, 2023 – A new priority research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 18, entitled, “Gene expression signatures of human senescent corneal and conjunctival epithelial cells.” In this new study, researchers Koji Kitazawa, Akifumi Matsumoto, Kohsaku Numa, Yasufumi Tomioka, Zhixin A. Zhang, Yohei Yamashita, Chie Sotozono, Pierre-Yves Desprez, and Judith Campisi from the Buck Institute for Research on Aging, Kyoto Prefectural University of Medicine and Lawrence Berkeley National Laboratory aimed to investigate the senescent phenotypes of human corneal and conjunctival epithelial cells. “Here, we induced cellular senescence in human corneal and conjunctival epithelium using X-irradiation, and analyzed gene expression profiles of each cell type to determine the characteristics of senescent ocular surface cells.” The team examined cell morphology, senescence-associated β-galactosidase (SA-β-gal) activity, cell proliferation, and expression of senescence markers (p16 and p21). RNA sequencing analysis was conducted to compare gene expression profiles between senescent and non-senescent cells. Finally, the potential involvement of senescent cells in the pathogenesis of ocular surface diseases was investigated. X-irradiated corneal and conjunctival epithelial cells exhibited typical senescence phenotypes, i.e., flattened morphologies, increased SA-β-gal activity, decreased cell proliferation, and increased expression of senescence markers, p16 and p21. RNA-seq analysis revealed substantial differences in gene expression profiles between senescent corneal (SCo) and conjunctival epithelial cells (SCj). Moreover, SCj were detected in pathological conjunctival tissues associated with limbal stem cell deficiency (LSCD) due to Stevens-Johnson syndrome or chemical burns, potentially being involved in abnormal differentiation. “This study highlights the cellular and molecular characteristics of senescent ocular surface cells, particularly in SCj that show abnormal keratin expression, and their potential roles in severe ocular surface diseases and pathology.” DOI - https://doi.org/10.18632/aging.205113 Corresponding authors - Koji Kitazawa - kkitazaw@koto.kpu-m.ac.jp, and Judith Campisi - jcampisi@buckinstitute.org Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205113 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, cornea, conjunctiva, Stevens-Johnson syndrome, limbal stem cell deficiency About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Join Kara Wada, an adult and pediatric allergy, immunology, and lifestyle medicine physician, as we discuss the epithelial barrier hypothesis. What is the epithelial barrier hypothesis? What are some of the diseases that have been linked to epithelial barrier dysfunction? What are some of the factors that can disrupt the epithelial barrier? How can we protect our epithelial barriers? What are some lifestyle changes that can help to improve epithelial barrier function? Find out the answers to these questions and more in this episode. Kara Wada is a board-certified academic adult and pediatric allergy, immunology, and lifestyle medicine physician, Sjogren's patient, certified life coach, TEDx speaker, and Dr. Midwest 2023. She can be reached at Dr. Kara Wada and on Instagram, YouTube, Facebook, and LinkedIn. She is a national expert, sought-after speaker, advisor, and host of the Becoming Immune Confident Podcast. She is CEO and founder, The Crunchy Allergist and the Virtual Sjogren's Summit, and serves as the director of clinical content for Aila Health. She discusses her KevinMD article, "How modern lifestyle changes are disrupting our immune systems." The Podcast by KevinMD is brought to you by the Nuance Dragon Ambient eXperience. With a growing physician shortage, increasing burnout, and declining patient satisfaction, a dramatic change is needed to make health care more efficient and effective and bring back the joy of practicing medicine. AI-driven ambient clinical intelligence promises to help by revolutionizing patient and provider experiences with clinical documentation that writes itself. The Nuance Dragon Ambient eXperience, or DAX for short, is a voice-enabled, ambient clinical intelligence solution that automatically captures patient encounters securely and accurately at the point of care. Physicians who use DAX have reported a 50 percent decrease in documentation time and a 70 percent reduction in feelings of burnout, and 83 percent of patients say their physician is more personable and conversational. Rediscover the joy of medicine with clinical documentation that writes itself, all within the EHR. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://earnc.me/UWrm6h Powered by CMEfy.

A new research paper was published on the cover of Aging (Aging-US) Volume 15, Issue 7, entitled, “p21 facilitates chronic lung inflammation via epithelial and endothelial cells.” Cellular senescence is a stable state of cell cycle arrest that regulates tissue integrity and protects the organism from tumorigenesis. However, the accumulation of senescent cells during aging contributes to age-related pathologies. One such pathology is chronic lung inflammation. p21 (CDKN1A) regulates cellular senescence via inhibition of cyclin-dependent kinases (CDKs). However, its role in chronic lung inflammation and functional impact on chronic lung disease, where senescent cells accumulate, is less understood. In this new study, researchers Naama Levi, Nurit Papismadov, Julia Majewska, Lior Roitman, Noa Wigoda, Raya Eilam, Michael Tsoory, Ron Rotkopf, Yossi Ovadya, Hagay Akiva, Ofer Regev, and Valery Krizhanovsky from the Weizmann Institute of Science aimed to elucidate the role of p21 in chronic lung inflammation. “[...] we subjected p21 knockout (p21-/-) mice to repetitive inhalations of lipopolysaccharide (LPS), an exposure that leads to chronic bronchitis and accumulation of senescent cells.” The researchers utilized a lipopolysaccharide (LPS) inhalation-induced chronic bronchitis procedure to study the effects of repetitive LPS exposure on p21 knockout (p21-/-) mice. Furthermore, the team aimed to examine the specific contribution of the epithelial, endothelial and immune compartments to chronic bronchitis pathology. They found that p21 knockout led to a reduced presence of senescent cells, alleviated the pathological manifestations of chronic lung inflammation, and improved the fitness of the mice. The expression profiling of the lung cells revealed that resident epithelial and endothelial cells, but not immune cells, play a significant role in mediating the p21-dependent inflammatory response following chronic LPS exposure. “Therefore, we suggest that p21-dependent elimination of senescent cells may limit the damage induced by the pro-inflammatory presence of senescent cells, but also promote tissue regeneration. Therefore, inhibition of p21 represents a promising strategy for limiting age-related inflammatory disorders in general and obstructive lung diseases in particular.” DOI: https://doi.org/10.18632/aging.204622 Corresponding Author: Valery Krizhanovsky - valery.krizhanovsky@weizmann.ac.il Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204622 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, chronic lung inflammation, p21 (CDKN1A) About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Dr. Ryan Conder is the Director of Epithelial and Organoid Systems at STEMCELL Technologies.  He talks about the next phase in organoid research and what questions organoids can help answer. He also discusses his experience doing a postdoc in Vienna, and Vancouver as a growing biotech hub.

Learn about where you see epithelial tissues, its characteristics & classifications.

References Clin Podiatr Med Surg . 2001 Jan;18(1):35-53 Biomedicines. 2021 Nov; 9(11): 1666 --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message

FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Josh Rabinowitz is a Professor of Chemistry and Integrative Genomics at Princeton University, where his research focuses on developing a quantitative, comprehensive understanding of cellular metabolism through the study of metabolites and their fluxes. In this episode, Josh focuses the discussion on three main topics: metabolomics, NAD (and its precursors), and cancer metabolism. The metabolomics discussion starts with a broad definition of metabolism, metabolites, and fluxomics before diving deep into glucose metabolism, lactate as a fuel, movement of lactate, and the regulation of these substrates. He then gives a detailed explanation of the electron transport chain and Krebs cycle and their implications with respect to both drugs and nutrition while also explaining how NAD is central to the process of energy generation. He then discusses the age-related decline in NAD and what current literature says about efforts to increase NAD through intravenous or oral supplementation with the precursors NMN and NR, including whether doing so provides any advantage to lifespan or healthspan. Finally, Josh ends the conversation talking about cancer metabolism and how one particular intersection between cancer metabolism and immunotherapy might provide a hopeful outlook on the future of cancer treatment. We discuss: Josh's background and unique path to becoming a research scientist at Princeton [3:30]; What sparked Josh's early interest in metabolism [11:15]; Metabolomics 101: defining metabolites and how they are regulated [16:30]; Fluxomics: metabolism as a system in action [26:00]; The Randle Hypothesis: glucose and fatty acids compete as substrates for oxidation [33:30]; The important role of lactate as an alternate fuel [36:30]; Fasting lactate levels as a potential early indicator of metabolic dysfunction [48:00]; The beauty of the Krebs cycle and the role of NAD in energy production [53:15]; How the drug metformin acts on complex I of the electron transport chain [1:05:00]; The difference between NADH and NADPH [1:08:45]; NAD levels with age, and the efficacy of supplementing with intravenous NAD [1:10:45]; The usefulness of restoring NAD levels and efficacy of oral supplementation with NAD precursors NR and NMN [1:22:15]; Exploring the hypothesis that boosting NAD levels is beneficial [1:32:30]; Cancer metabolism and the intersection with immunotherapy [1:39:00]; Making cancer a chronic disease: exploiting the metabolic quirks of cancer, augmenting the immune system, and more [1:46:15]; The challenge of treating pancreatic cancer [1:50:30]; Epithelial cancers that might respond to metabolic approaches to therapy [1:56:30]; Josh's hopeful outlook on the future of cancer treatment [1:59:00]; Nutritional approaches to cancer attenuation [2:00:15]; What makes Princeton University special [2:06:15]; More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

In this episode, Dr Matt and Dr Mike discuss the four tissues that make up the body. These include Epithelial, Connective, Nervous and Muscle tissue. This episode is great for anyone who wants to understand how the body is put together.

Dr. Shruti Naik is an Assistant Professor of Biological Sciences at New York University Langone Medical Center. She studies immunity in the epithelial tissues that line our body to understand how environmental stimuli collaborate with genetic factors to influence health and drive disease at these interfaces. She discusses the work she's presenting at the American Association of Immunologists' annual meeting, IMMUNOLOGY2022, on trained immunity and immune-epithelial crosstalk in tissue repair.

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

Michele De Luca, MD, shares his research in gene therapy for epidermolysis bullosa and cell therapy for ocular burns. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37671]

The Journal RETINA is devoted exclusively to diseases of the retina and vitreous.  These podcasts are intended to bring to its listeners summaries of selected articles published in the current issue of this internationally acclaimed journal.

In this episode, we review the high-yield topic of Epithelial Cell Junctions from the Dermatology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

Epithelium is one of the four basic tissue types (the other three are muscle tissue, nerve tissue, and connective tissue). It is found throughout the body—covering it; lining organs, vessels, and cavities; and forming glands. It absorbs nutrients, transports electrolytes, secretes hormones, and regulates body temperature by producing sweat. We begin with some general principles of how epithelial tissue is organized, and then we describe its various components. After listening to this AudioBrick, you should be able to: List the two types of epithelium (covering/lining and glandular) and describe their functions. Describe the structure and histologic features of epithelial tissue. Explain how covering/lining epithelium is classified. Describe the histologic features of glandular epithelium. Describe the five types of epithelial intercellular junctions. You can also check out the original brick on the Histology of Epithelial Tissue from our Musculoskeletal, Skin, and Connective Tissue collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/